FDA inspection
Anhui Haoyuan Pharmaceutical Co., Ltd. (Taodian Avenue Division): FDA inspection ending Aug 21, 2026
FDA inspection 1338630 · No Action Indicated (NAI) · Maanshan
Key facts
| Inspection ID | 1338630 |
|---|---|
| Firm | Anhui Haoyuan Pharmaceutical Co., Ltd. (Taodian Avenue Division) |
| FEI number | 3030636676 |
| City | Maanshan |
| Country | China |
| Fiscal year | 2026 |
| Inspection end date | Aug 21, 2026 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data